Camptosar, Onivyde pegylated liposomal (previously known as onivyde)(irinotecan)
Camptosar, Irinotecan, Onivyde (irinotecan) is a small molecule pharmaceutical. Irinotecan was first approved as Camptosar on 1996-06-14. It is used to treat breast neoplasms, colonic neoplasms, leukemia, lymphoma, and neoplasm metastasis amongst others in the USA. It has been approved in Europe to treat pancreatic neoplasms. The pharmaceutical is active against DNA topoisomerase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Camptosar, Irinotecan, Onivyde (discontinued: Irinotecan)
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| camptosar | New Drug Application | 2024-12-30 |
| irinotecan hydrochloide | ANDA | 2025-03-19 |
| irinotecan hydrochloide irinotecan hydrochloride | ANDA | 2022-03-03 |
| irinotecan hydrochloride | ANDA | 2025-01-16 |
| onivyde | New Drug Application | 2025-03-03 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
IRINOTECAN HYDROCHLORIDE, ONIVYDE, IPSEN | |||
| 2031-02-13 | ODE-463 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Irinotecan Hydrochloride, Onivyde, Ipsen | |||
| 10456360 | 2036-10-15 | DP | |
| 10993914 | 2036-10-15 | DP | |
| 9339497 | 2033-06-12 | U-1848 | |
| 9364473 | 2033-06-12 | U-1856 | |
| 9452162 | 2033-06-12 | U-1899 | |
| 9492442 | 2033-06-12 | U-1848, U-1899, U-1917 | |
| 9717724 | 2033-06-12 | U-1848, U-2091 | |
| 10980795 | 2033-06-12 | U-1848 | |
| 11369597 | 2033-06-12 | U-1848 | |
| 8147867 | 2028-08-29 | DS, DP | |
| 8329213 | 2027-01-06 | DS, DP | |
| 8703181 | 2025-05-02 | U-1434 | |
| 8992970 | 2025-05-02 | DS, DP | |
| 9724303 | 2025-05-02 | DS, DP | |
| 9730891 | 2025-05-02 | U-1848 | |
| 9782349 | 2025-05-02 | DS, DP | |
| 10722508 | 2025-05-02 | DS, DP | |
Clinical
Clinical Trials
1974 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | 1 | — | 2 | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | — | 2 | — | — | 1 | 3 |
| Carcinoma | D002277 | — | C80.0 | — | 2 | — | — | — | 2 |
| Cholangiocarcinoma | D018281 | — | C22.1 | — | 2 | — | — | — | 2 |
| Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | — | 1 |
| Neuroendocrine carcinoma | D018278 | — | — | — | 1 | — | — | — | 1 |
| Oncogenes | D009857 | — | — | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
| Bile duct neoplasms | D001650 | — | — | — | 1 | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | 1 | — | — | — | 1 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Irinotecan |
| INN | irinotecan |
| Description | Irinotecan is a member of the class of pyranoindolizinoquinolines that is the carbamate ester obtained by formal condensation of the carboxy group of [1,4'-bipiperidine]-1'-carboxylic acid with the phenolic hydroxy group of (4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2- hydrochloride]quinoline-3,14-dione. Used (in the form of its hydrochloride salt trihydrate) in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. It is converted via hydrolysis of the carbamate linkage to its active metabolite, SN-38, which is ~1000 times more active. It has a role as an apoptosis inducer, an EC 5.99.1.2 (DNA topoisomerase) inhibitor, an antineoplastic agent and a prodrug. It is a pyranoindolizinoquinoline, a N-acylpiperidine, a carbamate ester, a tertiary alcohol, a tertiary amino compound, a delta-lactone and a ring assembly. It is functionally related to a SN-38. It is a conjugate base of an irinotecan(1+). |
| Classification | Small molecule |
| Drug class | antineoplastics (camptothecin derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC |
Identifiers
| PDB | — |
| CAS-ID | 97682-44-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL481 |
| ChEBI ID | 80630 |
| PubChem CID | 60838 |
| DrugBank | DB00762 |
| UNII ID | 7673326042 (ChemIDplus, GSRS) |
Target
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 49,563 documents
View more details
Safety
Black-box Warning
Black-box warning for: Camptosar, Irinotecan hydrochloide, Irinotecan hydrochloide irinotecan hydrochloride, Irinotecan hydrochloride, Onivyde
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
38,191 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use